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Abstract: 
Background: Acute kidney injury (AKI) is a condition that leads to a rapid deterioration of renal 
function associated with impairment to maintain electrolyte and acid balance, and, if left  
untreated, ultimately irreversible kidney damage and renal necrosis. There are a number of 
causes that can trigger AKI, ranging from underlying conditions as well as trauma and surgery. 
Specifically, the global rise in surgical procedures led to a substantial increase of AKI incidence 
rates, which in turn impacts on mortality rates, quality of life and economic costs to the healthcare 
system. However, no effective therapy for AKI exists. Current approaches, such as  
pharmacological intervention, help in alleviating symptoms in slowing down the progression, but 
do not prevent or reverse AKI-induced organ damage.  
Methods: An in-depth understanding of the molecular machinery involved in and modulated by 
AKI induction and progression is necessary to specifically pharmacologically target key  
molecules. A major hurdle to devise a successful strategy is the multifactorial and complex  
nature of the disorder itself, whereby the activation of a number of seemingly independent  
molecular pathways in the kidney leads to apoptotic and necrotic events.  
Results: The renin-angiotensin-aldosterone-system (RAAS) axis appears to be a common element, 
leading to downstream events such as triggers of immune responses via the NFB pathway. Other 
pathways intricately linked with AKI-induction and progression are the tumor necrosis factor alpha 
(TNF) and transforming growth factor beta (TGF) signaling cascades, as well as a number of 
other modulators. Surprisingly, it has been shown that the involvement of the glutamatergic axis, 
believed to be mainly a component of the neurological system, is also a major contributor.  
Conclusions: Here we address the current understanding of the molecular pathways evoked in 
AKI, their interplay, and the potential to pharmacologically intervene in the effective prevention 
and/or progression of AKI.  
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number of tightly controlled and complex pro-
cesses are performed by the heterogeneous cell 
populations of the kidney, from blood filtration by 
microvascular endothelial cells and podocytes, and re-
absorption by proximal epithelial (tubular) cells to name 
a few. Acute kidney injury (AKI), also known as acute 
renal failure (ARF), is a common clinical event associated 
with a rapid loss of kidney function, leading to unac-
ceptable high morbidity and mortality.1 0.4% to 0.6% 
of the total healthcare costs, between £400m and 
£600m, are annually spent on treatment for acute kid-
ney injury in the UK alone  and as many as 22% of 
J Inj Violence Res. 2015 Jul; 7(2): 75-86. 
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hospitalized patients develop AKI.2 However, it is esti-
mated that one-fifth of AKI that occurs after hospital 
admission is predictable and avoidable.3 
Over the last 10 years several international guide-
line groups have tried to establish consistent definitions 
and staging systems for AKI, namely the RIFLE (Risk, 
Injury, Failure, Loss, End stage kidney disease) system,4 
which was modified by the AKIN (Acute Kidney Injury 
Network) group 5 and further developed by KDIGO 
(Kidney Disease: Improving Global Outcomes).6 The 
clinical assessment criteria for AKI are serum creatinine 
(SCr), blood urea nitrogen and urine output levels, 
whereby a rise in measurable quantities of SCr and 
blood urea associated with a decrease in urine levels is 
deemed indicative of AKI, especially if these occur rap-
idly within 48 hours. 
However, it is apparent that a definitive and timely 
diagnosis using those measures has its limitations and 
hampers a reliable clinical assessment, which as a con-
sequence can lead to serious diagnostic delays, poten-
tial misclassification of the actual injury status and stage, 
and offers a limited amount of information regarding 
the underlying cause. This in turn can result in a potential 
missed opportunity for therapeutic interventions at a 
point in time when kidney damage could be limitable or 
reversible.7 Unmanaged or delayed action can lead to 
a number of complications, including metabolic acidosis, 
high potassium levels, uremia, changes in body fluid 
balance, and effects to other organs, and ultimately 
organ failure.8 This delay between assessment and clini-
cal decision making has also been recognized as a po-
tential reason for poor clinical outcomes often associat-
ed with AKI,9 and it was suggested to use functional and 
injury biomarkers instead of, or in conjunction with, these 
clinical measures.10 
Nowadays, it has been widely recognized that AKI 
represents a multifactorial, heterogeneous syndrome, or 
a spectrum of diseases, that has the potential to be 
identified at an early stage, unlike the previous termi-
nology of ARF which assumed that each AKI-induction 
pathway follows a similar or identical molecular route.11 
This also explains the sometimes contradictory research 
findings, but at the same time has the potential to con-
fuse rather than solve the mystery surrounding AKI on a 
molecular level. Also, the identification of molecular 
events of renal impairment at an early stage would 
allow devising a suitable test that can be used for an 
immediate course of action to alleviate symptoms and 
disrupt the process of functional decline.12 It is impera-
tive that this condition is comprehensively understood on 
a molecular level to allow for targeted intervention 
therapies. 
 
Risk factors and triggers of AKI induction 
 
There is a considerable amount of clinical infor-
mation available relating to observed AKI cases over 
the last 30 years that allows a wide-ranging analysis of 
AKI predisposition and causative agents. General risk 
factors are age greater than 65 years, heart failure, 
liver disease, diabetes, chronic kidney disease with or 
without diabetes, sepsis, urological obstruction, iodinat-
ed contrast agents, nephrotoxic medication and 
hypovolaemia/shock.13 AKI can be induced by many 
different events such as rapid blood loss to and from 
the kidney, vasoconstrictive drugs, exposure to harmful 
substances, hypotension linked to sepsis, and obstruction 
of the urinary tract. Table 1 lists the main factors that 
can lead to AKI,14 where surgical procedures or medica-
tion are often precursors. 
Such a vast array of events leading to the same out-
come makes it impractical to devise general strategies 
to combat the onset of AKI using clinical measures alone. 
Nevertheless, this can be substantially improved if com-
mon and reliable indicators of tissue damage at an 
early stage can be demonstrated, especially if non-
invasive tools, such as the use of molecular biomarkers, 
can be employed. 
 
Biomarkers of AKI 
 
Currently, the main clinical objective regarding AKI is 
the prevention of disease onset due to the lack of suita-
ble and effective treatment and the irreversibility of 
organ damage. Monitoring disease onset and progres-
sion usually involves clinical markers such as SCr levels. 
However, SCr levels are known to be influenced by 
factors other than renal causes alone, lack the power of 
prediction due to its nature of being modulated after 
kidney irregularities and show low sensitivity.15 Other 
traditional clinical biomarkers of kidney injury observed 
in blood (urea nitrogen) and urine (epithelial cells, tubu-
lar casts, fractional excretion of Na+, urinary concen-
trating ability, etc.) have also been demonstrated to be 
insensitive and nonspecific for the diagnosis of AKI,16 
and therefore such measurements are a poor marker of 
acute deterioration in kidney function.17 This led to the 
search of potentially more reliant biomarkers, and over 
the last decade a considerable amount of studies were 
performed to identify specific molecular biomarkers 
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Promising diagnostic injury markers include kidney 
injury molecule 1 (KIM-1),16 interleukin 18 (IL-18),18 neu-
trophil gelatinase-associated lipocalin (NGAL),19 liver-
type fatty acid binding protein (L-FABP),20 cystatin C,21 
N-acetyl-beta-D-glucosaminidase (NAG),22 beta-2-
microglobulin (B2M),23 zinc-alpha-2-glycoprotein 
(AZGP1),24 and cytochrome C. 25 Furthermore, several 
additional biomarkers have been postulated to be of 
prognostic or diagnostic value in connection with AKI 
(reviewed in e.g.)10,17,26,27. 
KIM-1 is a promising marker for various renal dis-
eases as well as AKI, which includes but not limits to tub-
ular necrosis, since AKI incidence precedes any rise of 
the conventional SCr.28 KIM-1 expression is undetecta-
ble in normal kidneys, whereas the mRNA and protein 
levels are markedly up-regulated in AKI.29 
Urinary IL-18 was reported to be significantly ele-
vated in patients one to two days prior to an observed 
rise in SCr and confirmed AKI diagnosis.18 It has been 
shown to perform better as a predictive biomarker in 
children, 30 and multiple preclinical studies demonstrat-
ed that IL-18 is not only a biomarker but also a media-
tor of ischemic AKI.31 
NGAL is expressed during systemic inflammation 
and sepsis,15 and was found to be highly increased 
post-intervention in patients undergoing cardiac surgery 
and subsequently developing AKI compared to non-AKI 
patients undergoing the same treatment.32 It was shown 
in a cohort of more than 500 intensive care patients that 
it has a moderate prediction value for a predisposition 
to develop AKI. 33 NGAL as a clinical marker is now in 
clinical trial phase and undergoing prospective evalua-
tion after it was shown to be in accordance with altered 
serum creatinine levels as well as biopsy results in adult 
AKI patients.34 
L-FABP has been reported to be elevated in non-
diabetic CKD16 and in established AKI of diverse caus-
es, including acute tubular necrosis, sepsis, and 
nephrotoxin exposure.35 
Cystatin C, a marker for glomerular filtration rates 
that is freely reabsorbed by the glomerulus and 
catabolized by the tubulus, and was shown to be ele-
vated in tubular dysfunction.16 It was proposed to be an 
early onset marker for AKI in urine36 and serum.37 
Urinary NAG is a molecule shed from the proximal 
tubules into the urine. It is a proximal tubular damage 
marker and correlates with the grade of injury, and 
indeed has been shown to correlate with various diseas-
es and toxic agents affecting the kidneys, but also other 
diseases including rheumatoid arthritis and hyperthy-
roidism creating doubts on its specificity.16 
Table 1: Events leading to AKI induction. 
Site Trigger 
Pre-renal - Volume depletion due to hemorrhage, severe vomiting or diarrhea, burns 
 - Edema due to cardiac failure, cirrhosis, nephrotic syndrome 
 - Hypotension due to cardiogenic shock, sepsis, anaphylaxis 
 - Cardiovascular due to severe cardiac failure, arrhythmias 
 
- Renal hypoperfusion induced by non-steroidal anti-inflammatory drugs (NSAIDs) or specific enzyme inhibitors or 
receptor blockers involved in the renin-angiotensin axis, abdominal aortic aneurysm, renal artery stenosis or occlusion, 
hepatorenal syndrome 
Renal - Glomerular disease due to inflammation (glomerulonephritis), thrombosis, hemolytic uraemic syndrome 
 
- Tubular injury due to acute tubular necrosis following prolonged ischaemia, and nephrotoxins such as aminoglycosides, 
radiocontrast media, cisplatin, heavy metals 
 - Acute interstitial nephritis due to drugs (e.g. NSAIDs), infection or autoimmune diseases 
 
- Vascular disease including vasculitis, cryoglobulinaemia, polyarteritis nodosa, thrombotic microangiopathy, cholesterol 
emboli, renal artery stenosis, renal vein thrombosis, malignant hypertension 
 - Eclampsia 
Post-renal 
- Urinary tract obstructions due to Calculus formation (i.e. kidney stones), urethral stricture, prostatic hypertrophy or 
malignancy, blood clot 
 - Papillary necrosis 
 - Bladder tumor 
 - Radiation and retroperitoneal fibrosis 
 - Pelvic malignancy 
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B2M, the light chain of the major histocompatibility 
complex (MHC) I, which is present on every living cell, is 
shed normally but also usually reabsorbed by the prox-
imal tubular cells. In tubular damage situations it be-
comes present in urine, which has been shown in surgery 
and transplantation studies.16,27 
Serum levels of AZGP1, best known as a marker in 
cancer progression, were demonstrated in a small study 
to be increased in the early phase of AKI, and high 
initial levels of AZGP1 correlated with extra-renal 
complications but not with parameters of renal function. 
24 Elevated levels of extracellular cytochrome C is a 
bona fide indicator of cell death burden in any organ 
or tissue, and is released during mitochondrial damage 
as an initiator of apoptosis, necrotic cell lysis and oxi-
dative stress. It was observed in drug-induced AKI,25 
and holds potential as a marker for necrotic conditions. 
A recent meta-analysis of medium- to large-scale 
clinical/prospective studies indicated that the bi-
omarkers serum cystatin C and urinary IL-18 and NGAL 
showed the best performance for early diagnosis of 
AKI, serum cystatin C, urine IL-18 and KIM-1 were in-
dicative for the differential diagnosis of established 
AKI, and levels of urine NAG, KIM-1, and IL-18 per-
formed the best for mortality risk prediction after es-
tablished AKI.17 Some of these biomarker have already 
been proven to be elevated in patients developing AKI 
in different clinical settings such as patients in intensive 
care units (ICU), before and after heart or other sur-
gery, in diabetic or obese patients. Currently, however, 
they are not able to replace the conventional measured 
values like GFR, cystatin C, creatinine and urea. There is 
also hope that these novel biomarkers will discriminate 
between the underlying pathophysiology of AKI (i.e. 
toxins, sepsis, ischemia or multifactorial), and will enable 
to distinguish AKI from other renal disease such as 
chronic kidney disease.9 
A different approach to not only determine key fac-
tors and molecular modulators, but also pinpoint 
druggable targets, is the elucidation of molecular events 
such as downstream signaling cascades involved in renal 
insults. 
 
Molecular hallmarks and modulated pathways 
 
AKI can have many seemingly unrelated initiators, 
however commonalities converge on the affected organ, 
thereby enabling a much better view of how kidney 
damage is inflicted on a molecular level. It is suggested 
that renal cell loss, secondary to metabolic, genetic, 
immune, toxic, oxidant, and other mechanisms, is a com-
mon determining factor that can result in a broad spec-
trum of clinical renal syndromes.38 Molecular hallmarks 
of AKI are hyperglycaemia, vasoconstriction, accumula-
tion of free and esterified cholesterol, activation of the 
renin-angiotensin-aldosterone system (RAAS), inflamma-
tion and inflammatory response, altered tubule dynam-
ics leading to increased luminal sodium, hypoxia, cellu-
lar ATP depletion, renal apoptosis and necrosis (Table 
2) .39  
The major signaling cascades involved in AKI are the 
RAAS axis, tumor necrosis factor alpha (TNF), trans-
forming growth factor beta (TGF), epidermal growth 
factor receptor (EGFR), hypoxia inducing factor (HIF1α) 
and NFB pathways.40,41 A recent study integrated a 
majority of the various elements of AKI, delineated all 
potentially involved pathways and assembled them into 
a global molecular model of AKI induction, progression 
and ultimately apoptosis/necrosis using a combination 
of Systems Biology, proteomics and de-novo pathway 
mapping approaches.42 Additionally, a dataset from a 
proteomic study of chemically induced AKI was estab-
lished in this investigation and used to remove unsup-
ported pathways, thereby uncovering the involvement 
of the glutamatergic system in renal damage. 
A potential summary of AKI-modulated pathways 
and signaling events leading to Ca2+-overload and 
apoptosis as well as necrosis in kidney tissue after injury 
is shown in Figure 1. 
Potentially initiating factors such as TNF and other 
cytokines lead to activation of the RAAS cascade,43,44 
however induction of AKI can occur via multiple stimula-
tion or entry points,45 including vasoconstriction, which 
also activates the angiotensin receptor.46 These events 
lead to the activation of peroxisome proliferator-
activated receptor gamma (PPAR),47 which is involved 
in the expression/inhibition of gluconeogenesis pro-
teins.48  This can then lead to hyperglycemia via glyco-
gen phosphorylase activity.49 Hyperglycemia has also 
been shown to be chemically induced by 20-
hydroxyeicosatetraenoic acid (20-HETE) which involves 
the cAMP/protein kinase A-phosphorylase kinase-
glycogen phosphorylase pathway.50 
Vasoconstriction, one of the hallmarks of AKI, is in-
duced by RAAS,51 and has been shown to lead to hy-
poxic conditions,52 which in turn triggers the asymmetric 
gene activation of elements involved in the glycolysis 
pathway such as phosphofructokinase (PFKL).53 An ac-
cumulation of the PFKL metabolic product fructose 1,6-
bisphosphate can result in the inhibition of de novo ATP 
production and ultimately accumulation of hypoxan-
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Other downstream events of RAAS and hypoxia are 
the activation of the NFB signaling cascade,55 leading 
to inflammatory responses,56 and the 
cortisol/aldosterone receptor pathway, resulting in 
Table 2: Hallmarks of AKI. 
Hallmark * Modulated associated event 
RAAS activation ↑  Angiotensin signaling 
Na+/Cl- retention, increased luminal Na+ ↑  Aldosterone/cortisol signaling events 
Hyperglycemia ↑  Diabetes 
Tubular cell dynamics ↑  Infiltration of immature cells 
Cytoskeletal reorganization ↑  ECM remodeling 
Elevated blood pressure ↑  Hypertension 
Accumulation of free and esterified cholesterol ↑  Systemic stress response 
PI3K modulation ↓  Phosphoinositol-3-kinase activity 
 ↓  Insulin signaling 
Vasoconstriction ↑  Vasoconstrictors (endothelin, angiotensin, MMP2) 
 ↓  Vasodilators (nitric oxide NO) 
Hypoxia ↑  Hypoxia inducing factor HIF1α  
 ↑  NADPH oxidases 
 ↑  ROS levels 
 ↑  NFB activity 
 ↑  Inflammation factors (TNFα , TF, PAT1, MCP1) 
 ↑  Inflammation and inflammatory response 
 ↑  Atherogenesis, fibrinogenesis 
 ↓  ATP levels 
 ↓  NAD levels 
 ↑  Hypoxanthine levels 
 ↑  Necrosis 




Figure 1: Signaling cascades and evoked pathways involved in AKI. Known primary modulators of AKI (blue boxes) with downstream targets  
(yellow boxes) and hallmarks (green boxes) are shown. Grey boxes denote chemical compounds, and red boxes indicate endpoints in AKI. 
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Na+/Cl- -retention.57 The potential role of the function-
ally similar NFB2 has been postulated, 41 but remains 
currently un- 
clear. 
The activation of the RAAS axis also leads to a raise 
in intracellular Ca2+, either by targeting intracellular 
Ca2+-stores or induction of the glutamatergic system 
involving the N-methyl-D-aspartate (NMDA) receptor 
(NMDA-R). The latter might also require the production 
of reactive oxygen species (ROS) in a NADPH oxidase 
(NOX)-dependent pathway58 under hypoxic 
conditions,59 leading to gene activation of the NMDA-
R.60 It could also be shown that death associated protein 
kinase 1 (DAPK1), which is a gene activation target of 
the JNK-p53 system, is up-regulated in AKI. 42 This gene 
expression can also occur via TGF-mediated SMAD 
induction, 61 and has been shown to inhibit NFB activa-
tion by TNF-induced apoptosis. 62 Additionally, the 
NMDA-R is a known target of DAPK1, where DAPK1-
mediated channel modulation results in a permanently 
open NMDA-R, potentially leading to an uncontrollable 
elevation of intracellular Ca2+, nitric oxide (NO) and 
ROS, and ultimately to non-reversible cell death.63 This 
is directly associated with nuclear DNA damage, mito-
chondrial apoptotic pathway activation via calpain and 
caspase activation, and poly(ADP-ribose) 
glycohydrolase (PARG)-mediated necrosis involving 
molecular events described above.64,65 
Additionally, molecules involved in cytoskeletal reor-
ganization, cell integrity and extracellular matrix have 
also been shown to be induced in AKI, and their up-
regulation was suggested to be a cellular protective 
mechanism from angiotensin II- and high-glucose-
induced apoptosis.66 
 
The renal glutamatergic system 
 
Scant information is available on the involvement of 
the glutamatergic system in kidney function. The majori-
ty of molecular studies performed involving the 
glutamatergic system are in the area of neuroscience, 
where it could be demonstrated that different types of 
glutamate receptors are coupled to specific molecular 
signaling cascades.67 The NMDA-R in particular was 
shown to be tightly integrated in a vast molecular net-
work,68 and surprisingly many of these components 
were also not only found in kidney tissues, but also in 
conjunction with the NMDA-R up-regulated after AKI 
induction.42 The relevant endogenous NMDA-R ligand in 
AKI has not been characterized, however kidney gluta-
mate levels are increased in AKI,69 and expression of 
these proteins in tubular cells has been shown.70 A re-
cent study has shown that glutamate and NMDA-R pol-
yamine binding site agonist spermidine aggravated 
oxidative stress and ischemia-reperfusion-induced AKI,71 
reasoning that glutamate itself is the renal activator of 
the glutamatergic system. A simplified diagram of this 
system is shown in Figure 2. 
Renal receptors for glutamate modulated in AKI are 
the metabotropic glutamate receptor 1 (mGLUR1), α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor (AMPA-R) and the NMDA-R. 42 
mGluR1-signaling occurs via G-proteins, resulting in the 
activation of  phospholipase C beta (PLC).72 Thus, the 
intracellular Ca2+-release channel IP3-R, which is linked 
to this system via the mGluR1-scaffolder Homer,73 can 
be directly activated.74 This release of vesicular Ca2+ 
can activate calcineurin (PP2B), which is able to block 
calcium/calmodulin-dependent protein kinase type II 
(CamKII) indirectly via protein phosphatases 1 
(PP1).75,76 CamKII is a downstream target of NMDA-R 
activation,77 and is coupled to this receptor via scaf-
folders belonging to the disks large family DLGs,78 that 
also bind to the Ca2+/Na+-importer channel AMPA-R.79 
Nitric oxide synthase (NOS) is also bound to DLGs80 
and activated by CamKII,81 thereby linking NO-
production directly to NMDA-R activity. CamKII is also 
involved in protein tyrosine kinase 2 (Pyk2)82 and mito-
gen activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK)83 cascade activation, and 
both of those events can lead to a substantial number of 
diverse signaling end-points through various other cas-
cades and molecules involved. One example of con-
verging signaling is tyrosine-protein kinase Src that can 
be activated by Pyk2 phosphorylation,84 arachidonic 
acid (AA) modulation via phospholipase A 2 gamma 
(PLA2)85 downstream of MAPK/ERK,86 or 
diacylglycerol (DAG) induction by PLC and PKC activi-
ty,87 and can lead to the activation of the 
Ras/Rac/Cdc42 pathway.88,89 MAPK/ERK signaling can 
also result in gene activation events through phosphory-
lation of MSK1,90 and directly activates DAPK1,91 which 
in turn targets the NMDA-R. The NMDA-R has also been 
shown to be involved in cytoskeletal reorganization in 
neurons,92 but whether this is also the case in renal cells 
is currently unknown. However, the required molecular 
components are present in these cells. 
It has to be noted that this glutamatergic system 
might not exist in its entirety in a single cell, but is dis-
persed across several cell types, whereby ionotropic 
glutamate receptors and its associated signaling com-
ponents might be expressed in one type of cells, and 
the metabotropic receptor and associated signaling 
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Prevention and pharmacological intervention 
 
A considerable number of pharmacological or other 
intervention studies were performed to date due to the 
clinical importance of AKI. Summarily, inhibition of mole-
cules linked to the TNF-dependent modulation in the 
AKI-induced pathways, including ROS production, hy-
perglycemia and specific NFB-dependent signaling 
cascades, all had an improving or attenuated outcome 
(see overview of pharmacological intervention studies 
in).42 
Inhibition of TNF signaling by blocking the cognate 
receptor using anti-TNF antibodies resulted in preven-
tion of the induction of AKI.93 Targeting the penultimate 
step of Ca2+-overload by inhibiting NMDA-R using the 
channel blocker D-AP5 was shown to significantly re-
duce ischemia/reperfusion injury (I/RI) -induced glomer-
ular and tubular dysfunction,94 and raises the possibility 
that NMDA receptor signaling is one of the penultimate 
steps prior to non-reversible apoptosis and necrosis. 
However, inhibition of the NMDA-R in the clinical setting 
could be problematic due to the intricate involvement of 
this receptor in physiological processes occurring in neu-
romuscular junctions (e.g. heart) as well as cognitive 
functions.95 Nonetheless the NMDA-R channel blocker 
Mg2+ has been successfully used in the clinic manage-
ment of pre-eclampsia and eclampsia.96 
 Another molecule which gained considerable atten-
tion was sphingosine kinase-1 (SK1). It catalyzes the 
phosphorylation of sphingosine to form sphingosine 1-
phosphate (S1P), which in turn stimulates and promotes 
activation of NFB in response to TNF signaling and 
thereby diverting the AKI-induced stimulation of delete-
rious inflammation.97 It could be demonstrated that in-
terleukin 11 (IL-11), which is an approved chemothera-
py-induced thrombocytopenia treatment, induces this 
molecule via a HIF1-dependent pathway, resulting in 
powerful renal protective effects by reducing necrosis, 
inflammation, and apoptosis in ischemia-induced AKI.98 
Isoflurane administration in I/RI-induced AKI could also 
be shown to have the same downstream target as IL-11, 
where SK1 is induced through ERK MAPK activation, and 
 
 
Figure 2: Glutamatergic signaling cascades in renal tissue. Glutamate receptors NMDA-, AMPA- and metabotropic mGluR1 receptors, which 
are present and functional in tubular cells as well as podocytes, are depicted with potential associated signaling cascades ranging from calci-
um signaling to phospholipase and adenylate cyclase cascades and their interlinking pathways. Metabolites are depicted with a grey box, 
receptors in yellow, kinases in pink, phospholipases in orange, and phosphatases with a green box. Global parameters are shown with a blue 
box and scaffolders with a green ellipse. 
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resulted in protection against renal endothelial apopto-
sis.99 
Targeting the receptor of S1P has also shown great 
promise in AKI treatment. Using S1P as a pre-treatment 
prior to AKI induction in an I/RI animal model resulted in 
an attenuation of systemic inflammation and kidney 
injury,100,101 and the S1P receptor type 2 (S1P(2)R) an-
tagonist JTE013 selectively up-regulated SK1 and at-
tenuated both hydrogen peroxide-induced necrosis and 
TNFα/cycloheximide-induced apoptosis.102 
The compound TDZD-8, which targets and inhibits 
glycogen synthase kinase-3β, protects against 
endotoxemic acute renal failure mainly by down-
regulating pro-inflammatory TNF-α and RANTES. It was 
shown to ameliorate NSAID-induced AKI by induction of 
renal cortical COX-2 and direct inhibition of the mito-
chondrial permeability transition.103,104 
An as yet untested likely druggable target in AKI-
associated symptoms could be DAPK1 due to its direct 
link with the NMDA-R. This molecule has been shown to 
be a prospective target in cancer treatment by exploit-
ing its potential apoptotic action, however inhibition 
studies by chemical compounds are somewhat lacking. 
Nevertheless, one recent report of designed kinase in-
hibitors using octahedral metal chelate complexes with 
a ruthenium(II) or iridium(III) metal center demonstrated 
a highly selective octasporine protein kinase inhibitor 
termed OS4 with a DAPK1-IC50 of 2nM.105 Such a com-
pound deserves further investigation and shows a prom-
ising way forward in combating AKI-induced tissue inju-
ry. 
The results of pharmacological intervention studies 
reported in the literature suggest that AKI mediated 
tissue damage effects can be reduced and in principle 
even prevented or to some degree reversed, and a 
combination of various drugs, targeting specific AKI-
induced pathways and molecules, might potentially be a 





AKI currently remains a serious issue in clinical care and 
intervention therapies, however substantial advances in 
understanding the symptoms on a molecular level will 
undoubtedly lead to an improved way to devise novel 
therapy regimes and/or detection methods, and cur-
rently the best route of action is to prevent the occur-
rence of AKI in the first place, close monitoring of renal 
function and alleviating symptoms if kidney damage has 
occurred. 
Current research in AKI biomarker discovery has 
gone from strength to strength over the preceding years 
and it is only a matter of time to find the right marker(s) 
for each of the various causes of AKI. While potential 
proteinaceous molecular markers are under heavy in-
vestigation and close scrutiny, one should not ignore 
chemical metabolic markers of AKI, where prospective 
studies have not gained the same level of attention. 
These types of biomarkers might hold great potential to 
rapidly and reliably assess kidney damage in the clini-
cal setting. 
Therapeutic regimes by pharmacological interven-
tion in AKI prevention or progression have already 
yielded outstanding results and will quite likely be the 
best course of action. However, many compounds tested 
to treat or prevent AKI symptoms are unknown to be 
effective in humans, still need to be tested in larger 
cohorts, or approved to be used in the clinical setting. 
Future research for novel compounds could also be driv-
en by exploiting the molecular processes involved in 
AKI. This requires a better understanding of molecular 
events in the various facets leading to AKI symptoms. 
The current trend in AKI disease management, cou-
pled with a global effort to not only alleviate symp-
toms, but effectively combat AKI and challenge its root 
causes, holds great promise to tackle this issue head on 
and succeed in the not too distant future. 
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